Ibrutinib For Treatment of Lymphoma Cancer Produced for First Time in Iran

Ibrutinib tablets for the treatment of lymphoma cancer were produced by Zist Takhmir Company, one of the member companies of Pardis Technology Park.

CEO of Zist Takhmir Company Sahar Bahmani said that ibrutinib tablets have recently been introduced as an alternative to unsuccessful treatments for patients with lymphoma, and this type of treatment is also used in the country.

In addition to the production of medicine, the production of the active ingredient of this tablet is also on the agenda of the company and within the next few months, the production line of its active ingredient will also start in this company, she said.

With the introduction of this product, the domestic need for this drug will be eliminated, and about $10 million will be saved, she added.